Hardman Johnston Global Advisors LLC Sells 26,885 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Hardman Johnston Global Advisors LLC trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 11.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 202,170 shares of the medical research company’s stock after selling 26,885 shares during the quarter. IQVIA makes up 1.6% of Hardman Johnston Global Advisors LLC’s investment portfolio, making the stock its 19th largest position. Hardman Johnston Global Advisors LLC’s holdings in IQVIA were worth $39,728,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of IQV. FMR LLC boosted its stake in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in IQVIA during the third quarter worth approximately $147,683,000. JPMorgan Chase & Co. grew its holdings in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Nordea Investment Management AB raised its position in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the period. Finally, KBC Group NV lifted its stake in shares of IQVIA by 68.5% in the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after buying an additional 250,458 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Truist Financial reiterated a “buy” rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. UBS Group decreased their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Stephens initiated coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Finally, JPMorgan Chase & Co. reduced their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Stock Down 1.6 %

NYSE IQV opened at $190.94 on Monday. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock’s 50 day moving average is $199.57 and its two-hundred day moving average is $216.25. The company has a market capitalization of $33.62 billion, a price-to-earnings ratio of 25.46, a PEG ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director John G. Danhakl acquired 1,275 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.